If you have seen both amycretin and zenagamtide, you are not missing a new medicine each time. Zenagamtide is the newer name. It brings amylin and GLP-1 activity into one molecule.
The 24.3% weight-loss figure gets attention. I want to keep the particular study behind it in view.
Where did that number come from?
Dahl and colleagues studied injected amycretin in an early Phase 1b/2a trial involving 125 adults aged 18–55 with overweight or obesity. The trial had several parts; not all 125 people were in the comparison behind the headline. [1]
In one group, estimated average weight reduction at 36 weeks was 24.3%, compared with 1.1% with placebo.
The study mainly asked about safety and how manageable treatment was. Nausea, vomiting and diarrhoea were among the adverse events. A small, early trial cannot reliably tell us about uncommon harms or years of treatment.
There is a later study too
A separate Phase 2 trial in adults with type 2 diabetes was published online in The Lancet on 30 July 2026. Participants were already taking metformin, with or without another type of diabetes medicine called an SGLT2 inhibitor. Both trials were funded by Novo Nordisk. [2]
That is a different population and treatment setting from the 24.3% headline.
The amylin review published in September searched research up to June 2026. Its later publication date does not mean it includes every paper published in between. [3]
How I keep the story straight
I keep both names in mind when searching and keep oral and injected forms separate. Then I ask which study is relevant to the question, rather than which headline has the biggest number.
Read the sources
- Dahl et al. Subcutaneous amycretin, Phase 1b/2a.The Lancet, 2025 · Randomised trial; the source of the 24.3% result.
- Mora et al. Subcutaneous zenagamtide in type 2 diabetes.The Lancet · Online 30 July 2026 · Phase 2 randomised trial.
- Panou et al. Review of new amylin-based treatments.Diabetes Therapy · 28 September 2026 · Narrative review; search through June 2026.